USD 35.78
↓ -0.67 (-1.84%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| SWTX | -1.8 | 6.7 | 15.5 | -1.6 | -20.2 | 61.0 | -49.6 | 90.5 | 58.1 | 58.1 |
| S&P 500 | 0.6 | -1.3 | 0.7 | 6.4 | 11.4 | 29.9 | 25.6 | 89.2 | 187.9 | 33348.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | SWTX |
| name | SpringWorks Therapeutics, Inc. |
| price | 35.78 |
| changes percentage | -1.84 |
| change | -0.67 |
| day low | 35.46 |
| day high | 36.98 |
| year high | 53.92 |
| year low | 20.19 |
| market cap | 2661545392 |
| price avg 50 | 32.70 |
| price avg 200 | 40.17 |
| exchange | NASDAQ |
| volume | 230732 |
| avg volume | 1037778 |
| open | 36.98 |
| previous close | 36.45 |
| eps | -3.89 |
| pe | -9.20 |
| earnings announcement | 2024-11-12T05:00:00.000+0000 |
| shares outstanding | 74386400 |
| timestamp | 2024-11-18 16:39:04 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001773427 | |||
| revenue | 5447000 | 6147000 | -11.39 |
| gross profit | 5025000 | 4251000 | 18.21 |
| gross profit ratio | 0.92 | 0.69 | 33.40 |
| research and development expenses | 150487000 | 146122000 | 2.99 |
| operating expenses | 348038000 | 280674000 | 24.00 |
| interest income | 22947000 | 6285000 | 265.11 |
| interest expense | 0 | -765000 | 100.00 |
| ebitda | -341346000 | -280674000 | -21.62 |
| ebitdaratio | -62.67 | -45.66 | -37.25 |
| operating income | -343013000 | -280674000 | -22.21 |
| operating income ratio | -62.97 | -45.66 | -37.92 |
| net income | -325104000 | -274160000 | -18.58 |
| net income ratio | -59.68 | -44.6 | -33.82 |
| eps | -5.15 | -5.14 | -0.19 |
Revenue Growth: revenue decreased to 5 million in 2023 from 6 million in 2022 representing a change of -11.39%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 348 million in 2023 from 281 million in 2022 representing a change of 24.0%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -5.15 in 2023 from -5.15 in 2022 representing a change of -0.19%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Gross Profit: Gross Profit increased to 5 million in 2023 from 4 million in 2022 representing a change of 18.21%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 150 million in 2023 from 146 million in 2022 representing a change of 2.99%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -341 million in 2023 from -281 million in 2022 representing a change of -21.62%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -343 million in 2023 from -281 million in 2022 representing a change of -22.21%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -325 million in 2023 from -274 million in 2022 representing a change of -18.58%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001773427 | |||
| revenue | 49301000 | 59733000 | -17.46 |
| gross profit | 45960000 | 57280000 | -19.76 |
| gross profit ratio | 0.93 | 0.96 | -2.78 |
| research and development expenses | 42296000 | 44362000 | -4.66 |
| operating expenses | 103897000 | 102201000 | 1.66 |
| interest income | 0 | 6778000 | -100.00 |
| interest expense | 0 | 0 | NaN |
| ebitda | -57937000 | -44077000 | -31.44 |
| ebitdaratio | -1.18 | -0.74 | -59.26 |
| operating income | -57937000 | -44921000 | -28.98 |
| operating income ratio | -1.18 | -0.75 | -56.27 |
| net income | -53530000 | -39919000 | -34.10 |
| net income ratio | -1.09 | -0.67 | -62.47 |
| eps | -0.72 | -0.54 | -33.33 |
Revenue Growth: revenue decreased to 49 million in 2024Q3 from 60 million in 2024Q2 representing a change of -17.46%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 46 million in 2024Q3 from 57 million in 2024Q2 representing a change of -19.76%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 42 million in 2024Q3 from 44 million in 2024Q2 representing a change of -4.66%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 104 million in 2024Q3 from 102 million in 2024Q2 representing a change of 1.66%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.72 in 2024Q3 from -0.72 in 2024Q2 representing a change of -33.33%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -58 million in 2024Q3 from -44 million in 2024Q2 representing a change of -31.44%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -58 million in 2024Q3 from -45 million in 2024Q2 representing a change of -28.98%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -54 million in 2024Q3 from -40 million in 2024Q2 representing a change of -34.1%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001773427 | |||
| total assets | 725788000 | 630242000 | 15.16 |
| total liabilities | 99569000 | 72050000 | 38.19 |
| total equity | 626219000 | -569930000 | 209.88 |
| cash and cash equivalents | 176053000 | 67490000 | 160.86 |
| short term investments | 303149000 | 524722000 | -42.23 |
| long term investments | 185341000 | 8987000 | 1,962.32 |
| total current assets | 500912000 | 599760000 | -16.48 |
| total non current assets | 224876000 | 30482000 | 637.73 |
| total current liabilities | 78170000 | 51049000 | 53.13 |
| total non current liabilities | 21399000 | 21001000 | 1.90 |
| common stock | 7000 | 6000 | 16.67 |
| retained earnings | -895034000 | -569930000 | -57.04 |
| total debt | 7057000 | 5251000 | 34.39 |
Total Assets: Total Assets increased to 726 million in 2023 from 630 million in 2022 representing a change of 15.16%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 626 million in 2023 from -570 million in 2022 representing a change of 209.88%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 176 million in 2023 from 67 million in 2022 representing a change of 160.86%. This indicates an increase in available liquid assets.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 16.67%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 100 million in 2023 from 72 million in 2022 representing a change of 38.19%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 303 million in 2023 from 525 million in 2022 representing a change of -42.23%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 501 million in 2023 from 600 million in 2022 representing a change of -16.48%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 78 million in 2023 from 51 million in 2022 representing a change of 53.13%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -895 million in 2023 from -570 million in 2022 representing a change of -57.04%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 7 million in 2023 from 5 million in 2022 representing a change of 34.39%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001773427 | |||
| total assets | 608878000 | 617331000 | -1.37 |
| total liabilities | 76297000 | 60601000 | 25.90 |
| total equity | 532581000 | 556730000 | -4.34 |
| cash and cash equivalents | 84456000 | 79898000 | 5.70 |
| short term investments | 292163000 | 303987000 | -3.89 |
| long term investments | 121504000 | 138048000 | -11.98 |
| total current assets | 435111000 | 431324000 | 0.88 |
| total non current assets | 173767000 | 186007000 | -6.58 |
| total current liabilities | 70613000 | 54500000 | 29.57 |
| total non current liabilities | 5684000 | 6101000 | -6.83 |
| common stock | 7000 | 7000 | 0.00 |
| retained earnings | -1075868000 | -1022338000 | -5.24 |
| total debt | 6910000 | 7059000 | -2.11 |
Total Assets: Total Assets decreased to 609 million in 2024Q3 from 617 million in 2024Q2 representing a change of -1.37%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 76 million in 2024Q3 from 61 million in 2024Q2 representing a change of 25.9%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 533 million in 2024Q3 from 557 million in 2024Q2 representing a change of -4.34%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 292 million in 2024Q3 from 304 million in 2024Q2 representing a change of -3.89%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 71 million in 2024Q3 from 54 million in 2024Q2 representing a change of 29.57%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,076 million in 2024Q3 from -1,022 million in 2024Q2 representing a change of -5.24%. This indicates an accumulated losses.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 84 million in 2024Q3 from 80 million in 2024Q2 representing a change of 5.7%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 435 million in 2024Q3 from 431 million in 2024Q2 representing a change of 0.88%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 7 million in 2024Q3 from 7 million in 2024Q2 representing a change of -2.11%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001773427 | |||
| net change in cash | 108598000 | -36458000 | 397.87 |
| operating cash flow | -222795000 | -161563000 | -37.90 |
| free cash flow | -230180000 | -171759000 | -34.01 |
| capital expenditure | -7385000 | -10196000 | 27.57 |
| depreciation and amortization | 1667000 | 765000 | 117.91 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 94534000 | 72965000 | 29.56 |
| accounts payables | -196000 | 4168000 | -104.70 |
| inventory | -3103000 | 0 | NaN |
| acquisitions net | -2800000 | -4200000 | 33.33 |
| investments in property plant and equipment | -7385000 | -10196000 | 27.57 |
| net cash used for investing activites | 34754000 | -215597000 | 116.12 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 299300000 | 340066000 | -11.99 |
| common stock repurchased | -2800000 | -1341000 | -108.80 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 296639000 | 340702000 | -12.93 |
| cash at end of period | 176666000 | 68068000 | 159.54 |
| accounts receivables | -5930000 | 0 | NaN |
| cash at beginning of period | 68068000 | 104526000 | -34.88 |
Net Change in Cash: Net Change in Cash increased to 109 million in 2023 from -36 million in 2022 representing a change of 397.87%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 4 million in 2022 representing a change of -104.7%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -6 million in 2023 from 0 million in 2022 representing a change of nan%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -223 million in 2023 from -162 million in 2022 representing a change of -37.9%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -230 million in 2023 from -172 million in 2022 representing a change of -34.01%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -7 million in 2023 from -10 million in 2022 representing a change of 27.57%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 95 million in 2023 from 73 million in 2022 representing a change of 29.56%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001773427 | |||
| operating cash flow | -25379000 | -41790000 | 39.27 |
| free cash flow | -15976000 | -54015000 | 70.42 |
| capital expenditure | 9403000 | -12225000 | 176.92 |
| depreciation and amortization | 878000 | 844000 | 4.03 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 25963000 | 26245000 | -1.07 |
| accounts receivables | -8468000 | 0 | NaN |
| accounts payables | 1580000 | 745000 | 112.08 |
| inventory | -2108000 | 0 | NaN |
| acquisitions net | 8235000 | 0 | NaN |
| investments in property plant and equipment | 9403000 | -12225000 | 176.92 |
| net cash used for investing activites | 28648000 | 289000 | 9,812.80 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -10235000 | 0 | NaN |
| common stock repurchased | 7416000 | -919000 | 906.96 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 1291000 | 3371000 | -61.70 |
| net change in cash | 5179000 | -38130000 | 113.58 |
| cash at end of period | 85077000 | 79898000 | 6.48 |
| cash at beginning of period | 79898000 | 118031000 | -32.31 |
Net Change in Cash: Net Change in Cash increased to 5 million in 2024Q3 from -38 million in 2024Q2 representing a change of 113.58%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -25 million in 2024Q3 from -42 million in 2024Q2 representing a change of 39.27%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -16 million in 2024Q3 from -54 million in 2024Q2 representing a change of 70.42%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 26 million in 2024Q3 from 26 million in 2024Q2 representing a change of -1.07%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to -8 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Capital Expenditure: Capital Expenditure increased to 9 million in 2024Q3 from -12 million in 2024Q2 representing a change of 176.92%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 2 million in 2024Q3 from 1 million in 2024Q2 representing a change of 112.08%. This indicates that the company has increased its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.09 | 0.12 | -25.19 |
| net income per share | -5.15 | -5.14 | -0.11 |
| operating cash flow per share | -3.53 | -3.03 | -16.42 |
| free cash flow per share | -3.65 | -3.22 | -13.14 |
| cash per share | 7.59 | 11.11 | -31.69 |
| book value per share | 9.92 | 10.47 | -5.29 |
| tangible book value per share | 9.74 | 10.47 | -6.98 |
| shareholders equity per share | 9.92 | -10.69 | 192.76 |
| interest debt per share | 0.02 | -0.01 | 417.63 |
| market cap | 2304023664 | 1386086633.28 | 66.23 |
| enterprise value | 2135027664 | 1323847633.28 | 61.27 |
| pe ratio | -7.09 | -5.06 | -40.18 |
| price to sales ratio | 422.99 | 225.49 | 87.59 |
| pocfratio | -10.34 | -8.58 | -20.54 |
| pfcf ratio | -10.01 | -8.07 | -24.04 |
| pb ratio | 3.68 | -2.43 | 251.28 |
| ptb ratio | 3.68 | -2.43 | 251.28 |
| ev to sales | 391.96 | 215.36 | 82.00 |
| enterprise value over ebitda | -6.25 | -4.72 | -32.61 |
| ev to operating cash flow | -9.58 | -8.19 | -16.95 |
| ev to free cash flow | -9.28 | -7.71 | -20.34 |
| earnings yield | -0.14 | -0.2 | 28.66 |
| free cash flow yield | -0.1 | -0.12 | 19.38 |
| debt to equity | 0.0 | -0.0 | 299.92 |
| debt to assets | 0.0 | 0.0 | 90.75 |
| net debt to ebitda | 0.5 | 0.22 | 123.27 |
| current ratio | 6.41 | 11.75 | -45.46 |
| interest coverage | 0 | 366.89 | -100.00 |
| income quality | 0.69 | 0.58 | 17.67 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 36.27 | 21.89 | 65.69 |
| research and ddevelopement to revenue | 27.63 | 23.77 | 16.22 |
| intangibles to total assets | 0.02 | 0 | NaN |
| capex to operating cash flow | -0.03 | -0.06 | 47.48 |
| capex to revenue | 1.36 | 1.66 | -18.26 |
| capex to depreciation | 4.43 | 13.33 | -66.76 |
| stock based compensation to revenue | 17.36 | 11.87 | 46.21 |
| graham number | 33.91 | 35.18 | -3.64 |
| roic | -0.55 | 0.49 | -212.26 |
| return on tangible assets | -0.45 | -0.44 | -4.59 |
| graham net net | 6.11 | 9.76 | -37.41 |
| working capital | 422742000 | 548711000 | -22.96 |
| tangible asset value | 615019000 | 558192000 | 10.18 |
| net current asset value | 401343000 | 527710000 | -23.95 |
| invested capital | 458029000 | 566980000 | -19.22 |
| average receivables | 2965000 | 0 | NaN |
| average payables | 7703000 | 5719500 | 34.68 |
| average inventory | 1551500 | 0 | NaN |
| days sales outstanding | 397.37 | 0 | NaN |
| days payables outstanding | 6397.01 | 1542.01 | 314.85 |
| days of inventory on hand | 2683.87 | 0 | NaN |
| receivables turnover | 0.92 | 0 | NaN |
| payables turnover | 0.06 | 0.24 | -75.89 |
| inventory turnover | 0.14 | 0 | NaN |
| roe | -0.52 | 0.48 | -207.92 |
| capex per share | 0.12 | 0.19 | -38.85 |
ROE: Return on Equity (ROE) decreased to -0.52 on 2023-12-31 from 0.48 on 2022-12-31, representing a change of -207.92%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -7.09 on 2023-12-31 from -5.06 on 2022-12-31, representing a change of -40.18%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 6.41 on 2023-12-31 from 11.75 on 2022-12-31, representing a change of -45.46%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2023-12-31 from -0.00 on 2022-12-31, representing a change of 299.92%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| SWTX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.66 | 0.81 | -17.62 |
| net income per share | -0.72 | -0.54 | -33.84 |
| operating cash flow per share | -0.34 | -0.56 | 39.39 |
| free cash flow per share | -0.22 | -0.73 | 70.48 |
| cash per share | 5.07 | 5.18 | -2.08 |
| book value per share | 7.17 | 7.51 | -4.52 |
| tangible book value per share | 7.17 | 7.51 | -4.52 |
| shareholders equity per share | 7.17 | 7.51 | -4.52 |
| interest debt per share | 0.09 | 0.01 | 619.90 |
| market cap | 2379434612.04 | 2855882669.42 | -16.68 |
| enterprise value | 2301888612.04 | 2783043669.42 | -17.29 |
| pe ratio | -11.11 | -17.89 | 37.87 |
| price to sales ratio | 48.26 | 47.81 | 0.95 |
| pocfratio | -93.76 | -68.34 | -37.19 |
| pfcf ratio | -148.94 | -52.87 | -181.70 |
| pb ratio | 4.47 | 5.13 | -12.91 |
| ptb ratio | 4.47 | 5.13 | -12.91 |
| ev to sales | 46.69 | 46.59 | 0.21 |
| enterprise value over ebitda | -39.73 | -63.14 | 37.08 |
| ev to operating cash flow | -90.7 | -66.6 | -36.20 |
| ev to free cash flow | -144.08 | -51.52 | -179.65 |
| earnings yield | -0.02 | -0.01 | -60.95 |
| free cash flow yield | -0.01 | -0.02 | 64.50 |
| debt to equity | 0.01 | 0.0 | 654.00 |
| debt to assets | 0.01 | 0.0 | 631.31 |
| net debt to ebitda | 1.34 | 1.65 | -19.01 |
| current ratio | 6.16 | 7.91 | -22.14 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.47 | 1.05 | -54.71 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0.97 | -100.00 |
| research and ddevelopement to revenue | 0.86 | 0.74 | 15.52 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.37 | -0.29 | -26.65 |
| capex to revenue | 0.19 | 0.2 | -6.81 |
| capex to depreciation | 10.71 | 14.48 | -26.06 |
| stock based compensation to revenue | 0.53 | 0.44 | 19.86 |
| graham number | 10.78 | 9.54 | 13.04 |
| roic | -0.11 | -0.08 | -33.33 |
| return on tangible assets | -0.09 | -0.06 | -35.96 |
| graham net net | 4.44 | 4.66 | -4.69 |
| working capital | 364498000 | 376824000 | -3.27 |
| tangible asset value | 532581000 | 556730000 | -4.34 |
| net current asset value | 358814000 | 370723000 | -3.21 |
| invested capital | 389860000 | 401391000 | -2.87 |
| average receivables | 28738000 | 20016500 | 43.57 |
| average payables | 8771500 | 7450000 | 17.74 |
| average inventory | 8772000 | 6467000 | 35.64 |
| days sales outstanding | 60.19 | 36.92 | 63.03 |
| days payables outstanding | 260.06 | 289.45 | -10.15 |
| days of inventory on hand | 264.69 | 283.17 | -6.53 |
| receivables turnover | 1.5 | 2.44 | -38.66 |
| payables turnover | 0.35 | 0.31 | 11.30 |
| inventory turnover | 0.34 | 0.32 | 6.98 |
| roe | -0.1 | -0.07 | -40.18 |
| capex per share | 0.13 | 0.16 | -23.23 |
ROE: Return on Equity (ROE) decreased to -0.10 on 2024-09-30 Q3 from -0.07 on 2024-06-30 Q2, representing a change of -40.18%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 6.16 on 2024-09-30 Q3 from 7.91 on 2024-06-30 Q2, representing a change of -22.14%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -11.11 on 2024-09-30 Q3 from -17.89 on 2024-06-30 Q2, representing a change of 37.87%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.01 on 2024-09-30 Q3 from 0.00 on 2024-06-30 Q2, representing a change of 654.00%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 2.47 which is lower than current price 35.78, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-14 10:56:10
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sentiment: Positive
Publish Date: 2024-11-13 11:51:09
SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Sentiment: Positive
Publish Date: 2024-11-12 13:20:28
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participants Anupam Rama - JPMorgan Peter Lawson - Barclays Corinne Johnson - Goldman Sachs David Nierengarten - Wedbush Securities Alec Stranahan - Bank of America Operator Good morning. My name is Tanya, and I will be your conference operator today.
Sentiment: Negative
Publish Date: 2024-11-12 09:25:00
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET.
Sentiment: Negative
Publish Date: 2024-11-12 08:45:16
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $1.27 per share a year ago.
Sentiment: Neutral
Publish Date: 2024-11-12 06:30:00
– Achieved $49.3 million in OGSIVEO ® (nirogacestat) net product revenue in the third quarter –
Sentiment: Positive
Publish Date: 2024-11-11 07:00:00
– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment –
Sentiment: Positive
Publish Date: 2024-11-11 06:30:00
– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN –
Sentiment: Positive
Publish Date: 2024-11-07 06:30:00
– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a median duration of therapy of approximately 3 years –
Sentiment: Neutral
Publish Date: 2024-11-05 07:00:00
STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference, taking place in Boston, Massachusetts on Wednesday, November 13, 2024 at 1:00 p.m. ET.
Sentiment: Positive
Publish Date: 2024-11-04 12:17:12
Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding in place to get the company to profitability in the years ahead.
Sentiment: Negative
Publish Date: 2024-10-22 07:00:00
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates.
Sentiment: Neutral
Publish Date: 2024-09-06 12:38:01
SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?
Sentiment: Positive
Publish Date: 2024-09-05 10:57:04
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 61.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sentiment: Positive
Publish Date: 2024-08-29 12:55:19
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.
Sentiment: Negative
Publish Date: 2024-08-28 06:30:00
– PDUFA target action date of February 28, 2025 – – EU Marketing Authorization Application also validated by European Medicines Agency – STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for mirdametinib, an investigational MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Sentiment: Neutral
Publish Date: 2024-08-23 12:41:10
Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
